1[1]Blobel GA,Moll R,Franke WW,et al. The intermediate filament cytoskeleton of malinant mesotheliomas and its diagnostic significance. Am J Pathol, 1985, 121: 235.
3[3]Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol, 1998,22:1215.
4[4]Doglioni C,Dei Tos AP,Laurino L,et al. Calretinin:a novel immunocytochemical marker for mesothelioma. Am J Srug Pathol.1996,20:1037.
5[5]Ordonez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol,1999,112:75.
6[6]Delahaye M,Hoogsteden HC,Van der TH. Immunocytochemistry of malignant mesothelioma:OV632 as a marker of malignant mesothelioma. J Pathol, 1991,165:137.
7[7]Edwards C,Oates J. OV632 and MOC31 in the diagnosis of mesothelioma and adenocarcinoma:an assessment of their use in formalin-fixed and paraffin was embedded material. J Clin Pathol, 1995,48 : 626.
8[8]Jordan D, Jagirdar J,Kaneko M. Blood group antigens,lewisx and lewisy, in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol, 1989,135:931.
9[9]Ordonez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. Am J Clin Pathol, 1998,109: 85.
10[10]Peralta-Soler A,Knudsen KA,Jaurnd MC,et al. The differential expression of N-cadherin and E-cadherin distingsuihed pleural mesotheliomas from lung adenocarcinomas. Hum Pathol,1995,26:1363.
